dapagliflozin (Farxiga, Xigduo XR)

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35]

Introduction

FDA recommends approval Dec 2013.[2]

Indications

Contraindications

Dosage

  • stop 3 days prior to surgery

Dosage adjustment in renal failure

  • see Contraindications:

Adverse effects

Laboratory

Mechanism of action

Notes

  • dapagliflozin provides intermediate value compared with standard of care*

* based on ACC/AHA benchmarks[20]

More general terms

Component of

References

  1. ↑ Wilding JPH et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial. Ann Intern Med 2012 Mar 20; 156:405 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22431673
  2. ↑ 2.0 2.1 Pierson R FDA panel backs Bristol diabetes drug after prior rejection. Reuters, Dec 12, 2013 http://www.reuters.com/article/2013/12/12/us-bristolmyers-astrazeneca-diabetes-idUSBRE9BB19X20131212
  3. ↑ FDA News Release: Jan. 8, 2014 FDA approves Farxiga to treat type 2 diabetes. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm
  4. ↑ Prescriber's Letter 21(3): 2014 (subscription needed) http://www.prescribersletter.com
  5. ↑ 5.0 5.1 FDA MedWatch. May 15, 2015 SGLT2 inhibitors: Drug Safety Communication - FDA Warns Medicines May Result in a Serious Condition of Too Much Acid in the Blood. https://mail.google.com/mail/u/0/?tab=wm#inbox/14d587f1089e0791
  6. ↑ 6.0 6.1 FDA Safety Alert. June 14, 2016 Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR): Drug Safety Communication - Strengthened Kidney Warnings. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm506554.htm
  7. ↑ 7.0 7.1 7.2 Dandona P, Mathieu C, Phillip M et al Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. The Lancet Diabetes & Endocrinology. Sept 14, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/2891906 <Internet> http://thelancet.com/journals/landia/article/PIIS2213-8587(17)30308-X/fulltext
    Petrie JR SGLT2 inhibitors in type 1 diabetes: knocked down, but up again? The Lancet Diabetes & Endocrinology. Sept 14, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28919060 <Internet> http://thelancet.com/journals/landia/article/PIIS2213-8587(17)30315-7/fulltext
  8. ↑ 8.0 8.1 8.2 Monaco K Dapagliflozin Tied to Drop in Hepcidin Levels. Decrease may boost hematocrit and hemoglobin after SGLT-2 inhibitor therapy. MedPage Today. May 20, 2018 https://www.medpagetoday.com/meetingcoverage/aace/72989
    Ghanim H, et al Dapagliflozin Suppresses Plasma Hepcidin Concentrations. American Association of Clinical Endocrinologists (AACE) 2018; Abstract 228
  9. ↑ 9.0 9.1 Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2018 Nov 10 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30415602 https://www.nejm.org/doi/10.1056/NEJMoa1812389
  10. ↑ 10.0 10.1 10.2 American Diabetes Association Issues Critical Updates to the 2019 Standards of Medical Care in Diabetes. News Release. March 27, 2019 http://www.diabetes.org/newsroom/press-releases/2019/ada-issues-critical-updates-to-2019-standards-of-care.html
  11. ↑ 11.0 11.1 McMurray JJV, Solomon SF, Inzucchi SE et al Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med Sept 19, 2019 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31535829 https://www.nejm.org/doi/full/10.1056/NEJMoa1911303
    Fang JC Heart-Failure Therapy - New Drugs but Old Habits? N Engl J Med Sept 19, 2019 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31535828 https://www.nejm.org/doi/full/10.1056/NEJMe1912180
  12. ↑ 12.0 12.1 Nainggolan L FDA OKs Dapagliflozin to Reduce HF Hospitalization in Diabetes. Medscape - Oct 21, 2019. https://www.medscape.com/viewarticle/920093
  13. ↑ 13.0 13.1 Kosiborod M et al. Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: Results from the DAPA-HF Trial. Circulation 2019 Nov 17; PMID: https://www.ncbi.nlm.nih.gov/pubmed/31736335 Free PMC article. Clinical Trial. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044138
    Martinez FA et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: Insights from DAPA-HF. Circulation 2019 Nov 17 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31736328 Clinical Trial. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044133
    Petrie MC, Verma S, Docherty KF et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA 2020 Mar 27; 323:1353 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32219386 https://jamanetwork.com/journals/jama/fullarticle/2763950
  14. ↑ 14.0 14.1 FDA News Release. May 5, 2020 FDA approves new treatment for a type of heart failure. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-type-heart-failure
  15. ↑ 15.0 15.1 Heerspink HJL, Stefansson BV, Correa-Rotter R. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. September 24, 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32970396 https://www.nejm.org/doi/full/10.1056/NEJMoa2024816
  16. ↑ 16.0 16.1 Berg DD, Jhund PS, Docherty KF et al Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. Published online February 17, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33595593 https://jamanetwork.com/journals/jamacardiology/fullarticle/2776351
  17. ↑ 17.0 17.1 Butt JH, Docherty KF, Petrie MC et al Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction. A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. JAMA Cardiol. Published online March 31, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33787831 https://jamanetwork.com/journals/jamacardiology/fullarticle/2777811
  18. ↑ 18.0 18.1 Zelniker TA, Raz I, Mosenzon O et al Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes. A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. Published online April 14, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33851953 https://jamanetwork.com/journals/jamacardiology/fullarticle/2778552
  19. ↑ 19.0 19.1 Jeffry S FDA Approves Dapagliflozin (Farxiga) for Chronic Kidney Disease. Medscape - Apr 30, 2021. https://www.medscape.com/viewarticle/950329
  20. ↑ 20.0 20.1 Parizo JT, Goldhaber-Fiebert JD, Salomon JA et al Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. Published online May 26, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34037681 https://jamanetwork.com/journals/jamacardiology/fullarticle/2780359
    Chew DS, Mark DB Dapagliflozin - Does Cost Make 4-Pillar Heart Failure Therapy Too Herculean a Labor for Medicine? JAMA Cardiol. Published online May 26, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34037664 https://jamanetwork.com/journals/jamacardiology/fullarticle/2780365
  21. ↑ 21.0 21.1 Docherty KF, Jhund PS, Claggett B et al Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. JAMA Cardiol. Published online July 28, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34319398 https://jamanetwork.com/journals/jamacardiology/fullarticle/2782405
    Thomas LE, Navar AM, Pencina MJ Extrapolating Survival From Randomized Clinical Trial Data - Possibilities and Caution. JAMA Cardiol. Published online July 28, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34319362 https://jamanetwork.com/journals/jamacardiology/fullarticle/2782407
  22. ↑ 22.0 22.1 Butt JH et al. Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: A post hoc analysis of the DAPA-HF trial. Ann Intern Med 2022 Apr 26 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35467935 https://www.acpjournals.org/doi/10.7326/M21-4776
  23. ↑ 23.0 23.1 23.2 Medical Knowledge Self Assessment Program (MKSAP) 19 American College of Physicians, Philadelphia 2022
  24. ↑ Solomon SD et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022 Aug 27; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36027570 https://www.nejm.org/doi/10.1056/NEJMoa2206286
  25. ↑ 25.0 25.1 25.2 25.3 McCausland FR, Claggett BL, Vaduganathan M et al Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. A Prespecified Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol. Published online November 3, 2022. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36326604 https://jamanetwork.com/journals/jamacardiology/fullarticle/2798233
  26. ↑ 26.0 26.1 Schechter M et al. Effects of dapagliflozin on hospitalizations in patients with chronic kidney disease: A post hoc analysis of DAPA-CKD. Ann Intern Med 2022 Dec 6 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36469914 https://www.acpjournals.org/doi/10.7326/M22-2115
  27. ↑ 27.0 27.1 Desai AS et al Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction. A Participant-Level Pooled Analysis of DAPA-HF and DELIVER. JAMA Cardiol. 2022;7(12):1227-1234 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36189985 PMCID: PMC9531084 Free PMC article https://jamanetwork.com/journals/jamacardiology/fullarticle/2796866
  28. ↑ 28.0 28.1 28.2 Brooks M FDA Expands Use of Dapagliflozin to Broader Range of HF. Medscape. May 9, 2023 https://www.medscape.com/viewarticle/991736
  29. ↑ 29.0 29.1 Koshino A et al. Dapagliflozin and anemia in patients with chronic kidney disease. NEJM Evid 2023 Jun; 2:EVIDoa2300049. Not indexed in PubMed https://evidence.nejm.org/doi/10.1056/EVIDoa2300049
    Stefansson BV, Heerspink HJL, Wheeler DC et al Correction of anemia by dapagliflozin in patients with type 2 diabetes. J Diabetes Complications. 2020 Dec;34(12):107729. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32948397
  30. ↑ Engelhardt K, Ferguson M, Rosselli JL. Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors. Ann Pharmacother. 2021 Apr;55(4):543-548. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32808541 Review.
  31. ↑ 31.0 31.1 NEJM Knowledge+ Endocrinology
  32. ↑ 32.0 32.1 32.2 NEJM Knowledge+ Nephrology/Urology
  33. ↑ 33.0 33.1 Bersoff-Matcha SJ, Chamberlain C, Cao C et al Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med. 2019. May 7 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31060053 https://annals.org/aim/article-abstract/2732837/fournier-gangrene-associated-sodium-glucose-cotransporter-2-inhibitors-review-spontaneous
  34. ↑ 34.0 34.1 Mc Causland FR, Claggett BL, Vaduganathan M et al Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol. Published online November 12, 2023. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37952176 https://jamanetwork.com/journals/jamacardiology/fullarticle/2811979
  35. ↑ Highlights of Prescribing Information FARXIGA (dapagliflozin) tablets, for oral use https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/0be9cb1b-3b33-41c7-bfc2-04c9f718e442/0be9cb1b-3b33-41c7-bfc2-04c9f718e442_viewable_rendition__v.pdf

Database

Retrieved from "https://aaushi.info/w/index.php?title=A32680&oldid=1200720"